IL251147A0 - Fused pentacyclic imidazole derivatives - Google Patents
Fused pentacyclic imidazole derivativesInfo
- Publication number
- IL251147A0 IL251147A0 IL251147A IL25114717A IL251147A0 IL 251147 A0 IL251147 A0 IL 251147A0 IL 251147 A IL251147 A IL 251147A IL 25114717 A IL25114717 A IL 25114717A IL 251147 A0 IL251147 A0 IL 251147A0
- Authority
- IL
- Israel
- Prior art keywords
- imidazole derivatives
- fused pentacyclic
- pentacyclic imidazole
- fused
- derivatives
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290299 | 2014-10-03 | ||
| EP15162641 | 2015-04-07 | ||
| EP15171036 | 2015-06-08 | ||
| PCT/EP2015/072868 WO2016050975A1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251147A0 true IL251147A0 (en) | 2017-04-30 |
| IL251147B IL251147B (en) | 2020-05-31 |
Family
ID=54238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251147A IL251147B (en) | 2014-10-03 | 2017-03-14 | Fused pentacyclic imidazole derivatives |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10202405B2 (en) |
| EP (1) | EP3201196B1 (en) |
| JP (1) | JP6629847B2 (en) |
| KR (1) | KR102442235B1 (en) |
| CN (1) | CN107108672B (en) |
| AP (1) | AP2017009809A0 (en) |
| AU (1) | AU2015326798B2 (en) |
| BR (1) | BR112017006669B1 (en) |
| CA (1) | CA2962826C (en) |
| CL (1) | CL2017000787A1 (en) |
| CO (1) | CO2017003331A2 (en) |
| CR (1) | CR20170167A (en) |
| DK (1) | DK3201196T3 (en) |
| EA (1) | EA032839B1 (en) |
| EC (1) | ECSP17027306A (en) |
| ES (1) | ES2885432T3 (en) |
| GT (1) | GT201700044A (en) |
| HR (1) | HRP20211605T1 (en) |
| HU (1) | HUE056133T2 (en) |
| IL (1) | IL251147B (en) |
| LT (1) | LT3201196T (en) |
| MA (1) | MA40770B1 (en) |
| MX (1) | MX2017004201A (en) |
| MY (1) | MY181019A (en) |
| PE (1) | PE20170693A1 (en) |
| PH (1) | PH12017500414B1 (en) |
| PL (1) | PL3201196T3 (en) |
| RS (1) | RS62423B1 (en) |
| SG (1) | SG11201701796XA (en) |
| SI (1) | SI3201196T1 (en) |
| TN (1) | TN2017000083A1 (en) |
| TW (1) | TWI719949B (en) |
| UA (1) | UA120764C2 (en) |
| UY (1) | UY36341A (en) |
| WO (1) | WO2016050975A1 (en) |
| ZA (1) | ZA201701946B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017006669B1 (en) * | 2014-10-03 | 2023-04-18 | Ucb Biopharma Sprl | fused IMIDAZOLE PENTACYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND USE THEREOF |
| UY36630A (en) | 2015-04-17 | 2016-11-30 | Abbvie Inc | TRICYCLIC MODULATORS OF TNF SIGNALING |
| UY36628A (en) | 2015-04-17 | 2016-11-30 | Abbvie Inc | INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING |
| UY36629A (en) | 2015-04-17 | 2016-11-30 | Abbvie Inc | INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CA3019026A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| US10793578B2 (en) | 2016-04-01 | 2020-10-06 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| CA3018992A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused hexacyclic imidazole derivatives as modulators of tnf activity |
| CA3019245A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| GB201620948D0 (en) | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110461842A (en) * | 2017-03-15 | 2019-11-15 | Ucb生物制药私人有限公司 | Condensed five rings imdazole derivatives as TNF active regulator |
| KR102565132B1 (en) * | 2017-04-25 | 2023-08-08 | 유씨비 바이오파마 에스알엘 | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| WO2020084008A1 (en) | 2018-10-24 | 2020-04-30 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN113683505A (en) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | Preparation method of carboxylic ester compound containing oxygenated cyclobutyl |
| US20240247014A1 (en) * | 2022-11-23 | 2024-07-25 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449649A3 (en) | 1990-03-30 | 1992-09-02 | Arizona Board Of Regents, Arizona State University | Antineoplastic quinones and methods of using same |
| FR2832711B1 (en) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | TRIAZOLO [4,3-A] PYRIDO [2,3-D] PYRIMIDIN-5-ONES DERIVATIVES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PREPARATION AND USE |
| WO2004087720A1 (en) | 2003-03-10 | 2004-10-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| DE102008030206A1 (en) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-cyanoalky- and 3-hydroxyalkyl-indoles and their use |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| EP2721026B1 (en) | 2011-06-20 | 2016-03-02 | Vertex Pharmaceuticals Incorporated | Phosphate esters of gyrase and topoisomerase inhibitors |
| CA2874303C (en) * | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| CN104619709B (en) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | Imidazopyridine derivatives as TNF active regulator |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| AU2014338549B2 (en) | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2744460C2 (en) | 2014-04-15 | 2021-03-09 | Вертекс Фармасьютикалз Инкорпорейтед | Pharmaceutical compositions for treating diseases mediated by cystic fibrosis transmembrane conductance regulator |
| BR112017006669B1 (en) * | 2014-10-03 | 2023-04-18 | Ucb Biopharma Sprl | fused IMIDAZOLE PENTACYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITION INCLUDING THEM AND USE THEREOF |
-
2015
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/en active IP Right Grant
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 EA EA201790734A patent/EA032839B1/en not_active IP Right Cessation
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/en unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 MX MX2017004201A patent/MX2017004201A/en unknown
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en active Application Filing
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/en active Active
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/en active
- 2015-10-02 TW TW104132631A patent/TWI719949B/en active
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/en active IP Right Grant
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/en unknown
- 2015-10-02 CR CR20170167A patent/CR20170167A/en unknown
- 2015-10-02 MA MA40770A patent/MA40770B1/en unknown
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/en unknown
- 2015-10-02 SI SI201531711T patent/SI3201196T1/en unknown
- 2015-10-02 UA UAA201702002A patent/UA120764C2/en unknown
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/en unknown
- 2015-10-02 UY UY0001036341A patent/UY36341A/en not_active Application Discontinuation
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/en active Active
- 2015-10-02 ES ES15771976T patent/ES2885432T3/en active Active
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 PL PL15771976T patent/PL3201196T3/en unknown
- 2015-10-02 RS RS20211235A patent/RS62423B1/en unknown
-
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/en unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/en unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/en unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/en unknown
-
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
-
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201701946B (en) | Fused pentacyclic imidazole derivatives | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| PT3131898T (en) | Fluoroalkylfluorene derivatives | |
| EP3140315C0 (en) | New cath2 derivatives | |
| HRP20182016T1 (en) | Ethynyl derivatives | |
| IL248773A0 (en) | Naphthyridinedione derivatives | |
| EP3099672A4 (en) | Fused imidazole compounds | |
| HK1245269A1 (en) | Imidazole derivatives | |
| PL3164393T3 (en) | Flavagline derivatives | |
| IL248629A0 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| PL3119744T3 (en) | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives | |
| IL248900A0 (en) | Pyrazine derivatives | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| PL3228616T3 (en) | Pyridine derivatives | |
| PT3201196T (en) | Fused pentacyclic imidazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |